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CDH1 and IL1-beta expression dictates FAK
and MAPKK-dependent cross-talk between
cancer cells and human mesenchymal stem
cells
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and Nehad M. Alajez1*
Abstract
Introduction: Tumor microenvironment conferred by stromal (mesenchymal) stem cells (MSCs) plays a key role in
tumor development, progression, and response to therapy. Defining the role of MSCs in tumorigenesis is crucial for
their safe utilization in regenerative medicine. Herein, we conducted comprehensive investigation of the cross-talk
between human MSCs (hMSCs) and 12 cancer cell lines derived from breast, prostate, colon, head/neck and skin.
Methods: Human bone marrow-derived MSC line expressing green fluorescence protein (GFP) (hMSC-GFP) were
co-cultured with the following cancer cell lines: (MCF7, BT-20, BT-474, MDA-MB-468, T-47D, SK-BR-3, MDA-MB-231,
PC-3, HT-29, MDA-MB-435s, and FaDu) and changes in their morphology were assessed using fluorescent
microscopy. For cellular tracking, cells were labeled with Vybrant DiO, DiL, and DiD lipophilic dyes. Time-lapse
microscopy was conducted using Nikon BioStation IM-Q. Stable expression of mCherry, and luciferase genes was
achieved using lentiviral technology. IL1-Beta neutralizing experiments were conducted using soluble recombinant
IL-1R (srIL-1R). Changes in gene expression in sorted hMSCs were assessed using Agilent microarray platform while
data normalization and bioinformatics were conducted using GeneSpring software.
Results: We observed a dynamic interaction between cancer cells and hMSCs. High CDH1 (E-cadherin) and low
IL1-Beta expression by cancer cells promoted reorganization of hMSCs into a niche-like formation, which was
dependent on direct cell-cell contact. Our data also revealed transfer of cellular components between cancer cells
and hMSCs as one possible mechanism for intercellular communication. Global gene expression analysis of sorted
hMSCs following co-culturing with MCF7 and BT-20 cells revealed enrichment in signaling pathways related to
bone formation, FAK and MAPKK signaling. Co-culturing hMSCs with MCF7 cells increased their growth evidenced
by increase in Ki67 and PCNA staining in tumor cells in direct contact with hMSCs niche. On the other hand,
co-culturing hMSCs with FaDu, HT-29 or MDA-MB-231 cells led remarkable decline in their cell growth.
Conclusions: Dynamic interaction exists between hMSCs and cancer cells. CDH1 and IL1-Beta expression by cancer
cells mediates the crosstalk between hMSCs and cancer cells. We propose a model where hMSCs act as the first
line of defense against cancer cell growth and spread.
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Introduction
Carcinogenesis is a complex process that involves
transformed cells interacting with the microenvironment
containing extracellular matrix, carcinoma-associated fi-
broblasts (CAFs), pericytes, endothelial cells, and immune
cells [1]. Cross-talk between transformed cells and the
microenvironment contributes to tumor growth, invasion,
and metastasis. Among tumor microenvironment compo-
nents, growing evidence suggests that CAFs are derived
from mesenchymal (stromal) stem cells (MSCs), which
are multipotent stem cells present within the stroma of
bone marrow and probably other organs [2]. The precise
role of CAFs or MSCs in cancer development and pro-
gression is an area of intensive investigation and remains
controversial (for a review see [3]). For instance, Karnoub
et al. [4] reported that MSCs in a breast cancer xenograft
model promoted breast cancer invasion and metastasis via
the chemokine (C–C motif) ligand/C–C chemokine re-
ceptor CCL5/CCR5 cytokine network. Similarly, Liu et al.
[5] reported that MSCs promoted breast cancer stem cell
expansion via interleukin (IL)-6 and chemokine (C–X–C
motif) ligand 7 signaling. In another study, Huang et al.
[6] demonstrated that activation of caspase 3 by tumor or
stroma cells triggers tumor repopulation during radiation
therapy. While these reports suggest a pro-tumorigenic
role for MSCs, a number of other studies revealed an anti-
tumor effect of MSCs. For example, Cooke et al. [7] have
shown that targeted depletion of pericytes (which are part
of the MSC lineage) in vivo promoted tumor metastasis,
which was mediated via hypoxia-induced epithelial to
mesenchymal transition. Also, Khakoo et al. [8] have re-
ported a strong inhibitory effect of human bone marrow-
derived MSCs (hMSCs) against Kaposi sarcoma in vitro
and in vivo through inhibition of AKT signaling in tumor
cells. The precise role of MSCs in tumorigenicity and the
conditions under which MSCs exert pro-tumor or anti-
tumor effects therefore need to be determined.
In the majority of previous studies, a single or a few tumor
models were studied, which limits the generalizability of
their findings to other tumor models. In the present study,
we conducted a comprehensive investigation to characterize
the cellular and molecular phenotype of hMSCs co-cultured
with 12 cancer cell lines derived from the breast, colon,
prostate, head and neck, and melanoma. Our data revealed
that the outcome of MSC–tumor interaction is dependent
on the nature rather than the type of tumor cells and that
epithelial cadherin type 1 (CDH1) and IL-1β expression
by tumor cells are key factors in determining the outcome
of hMSC–tumor cross-talk.
Methods
Cell lines and culture
Tumor cell lines used in this study (breast: MCF7,
MDA-MB-231, BT-20, BT-474, MDA-MB-468, T-47D,
and SKB-R3; melanoma: MDA-MB-435S; prostate: PC-3;
head and neck: FaDu; and colon: HT-29 and COLO-
320) were purchased from Cell Lines Service GmbH
Eppelheim, (Germany) or were obtained from other
sources and subsequently authenticated by Genetica
DNA Laboratories, Inc. Burlington, (NC, USA). As a
model for primary hMSCs, we employed a well-
characterized telomerized hMSC line (hMSC-TERT) that
has been created through overexpression of the human
telomerase reverse transcriptase gene (TERT) [9]. The
hMSC-TERT cell line expresses all known markers of
primary hMSCs [10, 11] and exhibits hMSC “stemm-
ness”, evidenced by being able to form bone and the
bone marrow microenvironment following in-vivo im-
plantation [12]. hMSC-TERT cells were also engineered
to express enhanced green fluorescent protein (GFP)
gene [13]. All cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
4500 mg/l D-glucose, 4 mM L-glutamine, and 110 mg/l
sodium pyruvate, 10 % fetal bovine serum (FBS), 1 %
penicillin–streptomycin and nonessential amino acids.
The normal, nontransformed human mammary epithe-
lial cell line (MCF10A) was maintained in universal
medium (DMEM-F12 + 20 ng/ml human epidermal
growth factor (EGF), 100 ng/ml cholera toxin, 0.01 mg/
ml insulin, 500 ng/ml hydrocortisone, and 5 % FBS). Pri-
mary normal adipose tissue-derived MSCs (AT-MSCs)
were obtained and cultured as described previously [14].
Co-culture experiments
For co-culture experiments, hMSCs were trypsinized,
counted, and seeded at 0.5 × 105/well, and 1 × x105
tumor cells were added to the same well in 24-well cul-
ture plates (Falcon, Franklin Lake, NJ, USA). Co-cultures
were subsequently monitored and images were taken at
the indicated time points using a Nikon® ECLIPSE Ti-U
inverted fluorescence microscope, (Nikon, Tokyo, Japan).
Cells were either imaged directly or were washed with
1× phosphate-buffered saline (PBS), followed by staining
with Hoechst 33342 (10 μg/ml) in PBS for 10 minutes at
37 °C. Recombinant human IL-1β was purchased from
(Invitrogen, Carlsbad, CA, USA). Focal adhesion kinase
(FAK) inhibitor (PF-573228), mitogen-activated protein
kinase kinase (MAPKK) inhibitor (PD98059), and cyto-
chalasin D were purchased from Sigma (St. Louis, MO,
USA) and were reconstituted in dimethyl sulfoxide
(DMSO). For experiments involving IL-1β or the above-
mentioned small molecule inhibitors, the agents were
added from day 0 of the experiment as indicated in each
figure.
Vybrant® multicolor cell labeling
Cells were harvested and suspended at a density of 1 ×
106/ml in serum-free culture DMEM followed by
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fluorescence-labeling with the relevant Vybrant® Cell-
Labeling Solution (Invitrogen, Carlsbad, CA, USA) as
per the manufacturer’s protocol. AT-MSCs were labeled
with green fluorescent probe (DiO), while the MCF7 cell
line was labeled with DiL or DiD probes. Subsequently,
direct co-culturing was performed by seeding the labeled
primary hMSCs and the labeled MCF7 cells into 24-well
culture plates at density of 1 × 105/ml/well for each cell
type. Co-cultures were visualized and images were taken
on the indicated days.
Lentiviral transduction and time-lapse microscopy
Lentiviral particles encoding for mcherry or firefly lucif-
erase were purchased from Genecopoeia Inc. (Rockville,
MD, USA). Then 100,000 tumor cells were seeded in
complete DMEM in a 24-well plate. Forty-eight hours
later (~80 % confluency), the medium was removed and
then 20 μl crude lentiviral particles in 500 μl DMEM+
5 % heat-inactivated serum (Invitrogen), 1 % penicillin–
streptomycin supplemented with polybrene (8 μg/ml;
Sigma) were added to the cells. Seventy-two hours later,
the medium was removed and transduced cells were se-
lected with puromycin (1 μg/ml; Sigma) for 1 week until
stably-transduced cells were generated. Time-lapse mi-
croscopy was conducted using Nikon® BioStation IM-Q.
Magnetic activated cell sorting
Direct co-culture of MCF7 (seeding number = 1.0 × 105/
well) or BT-20 (seeding number = 1.0 × 105/well) cells
and hMSCs (seeding number = 0.5 × 105/well) was con-
ducted using BD Falcon 24-well culture plates. On day 7
when the niche-like structure was visible, co-cultured
cells were trypsinized from three replicas, and washed
once with 1× PBS. Cells were subsequently resuspended
in sorting buffer (500 ml Ca2+/Mg2+ free PBS supple-
mented with 2 mM ethylenediamine tetraacetic acid
(EDTA) and 0.5 % bovine serum albumin (BSA)), which
was subsequently filtered using a 0.22 μM filter. Sorting of
hMSCs from MCF7 or BT-20 co-cultures was performed
using the CD326 (EpCAM) MicroBeads kit (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) as per the
manufacturer’s recommendations. Purity of sorted cells
was confirmed using the BD FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA). Sorted cells were
then washed with 1× PBS and were kept at −80 °C. Cells
from the same batch and passage number of hMSCs were
used as control.
Gene expression microarray
Total RNA was isolated using total RNA Purification Kit
(Norgen-Biotek Corp., Thorold, ON, Canada) according
to the manufacturer’s instructions. The concentrations
and purity of total RNA were measured using NanoDrop
2000 (Thermo-Scientific, Wilmington, DE, USA). Extracted
RNA was labeled and then hybridized to the Agilent Hu-
man SurePrint G3 Human GE 8 × 60 k microarray chip
(Agilent Technologies, Santa Clara, CA, USA). All micro-
array experiments were conducted at the Microarray Core
Facility (Stem Cell Unit, King Saud University College
of Medicine, Riyadh, Saudi Arabia) as described previ-
ously [15]. Data analyses were conducted using Gene-
Spring GX software (Agilent Technologies) as described
[16, 17]. Microarray data were deposited in the Gene
Expression Omnibus [GEO:GSE70103].
Quantification of gene expression using qRT-PCR
Expression levels of selected genes were assessed using
qRT-PCR. Reverse transcription was performed on
500 ng total RNA using High Capacity Reverse Tran-
scriptase Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s specifications. The qRT-
PCR was carried out using FAST-SYBR Green Master
Mix (Applied Biosystems) and the ViiA™ 7 Real-Time
PCR Detection System (Applied Biosystems). Primers
used for gene expression analysis are presented in
Additional file 1 and were either published previously or
were designed using NCBI Primer-BLAST [18]. The
2ΔCT value method was used to calculate relative ex-
pression of miRNAs and mRNAs [19].
Alkaline phosphatase staining
hMSCs were co-cultured with MCF7 or HT-29. On day
7, the cells were washed in PBS, fixed in 10 mM acet-
one/citrate buffer (1.5:1) at pH 4.2 for 5 minutes at room
temperature, and incubated with alkaline phosphatase
(ALP) substrate solution (naphthol AS-TR phosphate
(Sigma) prepared 1:5 in water plus 10 mg Fast red TR
(Sigma), in 24 ml of 0.1 M Tris buffer, pH 9.0) for 1 hour
at room temperature. Cells were rinsed with water, stored
in PBS, and photographed using a Nikon® ECLIPSE Ti-U
inverted fluorescence microscope.
Immunofluorescence staining
Day 7 MCF7–MSC co-cultures were fixed with metha-
nol/acetone 1:1 (vol/vol) for 30 minutes at −20 °C. After
fixation, cells were dried for 15 minutes and rehydrated
with PBS for 15 minutes. Cells were blocked with 2 %
BSA (Sigma) for 1 hour, followed by incubating with
rabbit primary antibodies against Ki67 (1:200, ab15580;
Abcam, Cambridge, MA, USA) or Proliferating cell nu-
clear antigen (PCNA) (1:100, ab2426; Abcam) in block-
ing solution at 4 °C overnight. After removal of primary
antibodies, cells were washed three times with PBS,
and then Alexa Fluor® 488 conjugated goat anti-rabbit
IgG (H + L) secondary antibody (1/1000, A11008; Life-
technologies, Carlsbad, CA, USA) was added and incu-
bated for 2 hours at room temperature. Cells were
washed three times with PBS and counterstained with
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4′,6-diamidino-2-phenylindole (DAPI) nuclear dye, mounted
on slides in CC/Mount (C9368; Sigma), and were ob-
served under a Nikon®ECLIPSE Ti fluorescence microscope.
Flow cytometry
All flow cytometry experiments were conducted using
the BD FACSCalibur flow cytometer (BD Biosciences).
Cell counting
For counting tumor and hMSC cells from co-culture
experiments, we employed the following strategy. Co-
cultured cells were trypsinized and then the percentage of
hMSC cells (GFP+) and tumor (GFP–) was determined
using fluorescence-activated cell sorting (FACS). The total
number of cells in the co-culture per sample was deter-
mined using an automated cell counter (Vi-Cell XR cell
viability analyzer; Beckman Coulter Inc, Fullerton, CA,
USA). The number of hMSCs was calculated using the
following equation:
hMSCs ¼ % GFPþ
 total number of cells and the number of tumor cells
¼ % GFP‐  total number of cells:
For selected experiments, the relative number of hMSCs
was determined as follows. hMSCs 0.5 × 104 were cultured
alone or with MCF7 (0.5 × 103) or HT-29 (0.5 × 103) cells
in Corning® polystyrene flat-bottomed 96-well TC-treated
black microplates Cambridge, MA, USA. The fluorescence
signal was measured using a SpectraMax/M5 fluorescence
spectrophotometer plate reader (Molecular Devices Co.,
Sunnyvale, CA, USA USA) using the bottom well-scan
mode where nine readings per well were obtained using
Ex (488 nm) and Em (509 nm) spectra. For luminescence
measurements, hMSCs and tumor cells were cultured as
above in Nunc™ F96 MicroWell™ white plates (Thermo-
Scientific, Wilmington, DE, USA), and luminescence was
measured using a BioTek Synergy II microplate reader
(BioTek Inc., Winooski, VT, USA) with the ONE-Glo™
Luciferase Assay System (Promega, Madison, WI, USA).
Scratch assay
HT-29 and MCF7 cells were cultured alone or were co-
cultured with hMSCs, and on day 7 the scratch assay
was performed using a p200 pipette tip. The scratch area
was imaged on day 0 and day 2 using 4× magnification with
the Nikon® ECLIPSE Ti-U inverted fluorescence micro-
scope. Data are representative of at least three replicates.
Statistical analysis
Statistical analyses and graphing were performed using
Microsoft Excel 2010 (Microsoft, Mountain View, CA)
and Graphpad Prism 6.0 software (Graphpad Software,
San Diego, CA, USA). P values were calculated using the
two-tailed t test and P <0.05 was considered statistically
significant.
Results
Changes in hMSC morphology when co-cultured with
cancer cell lines
We have previously reported significant changes in
hMSC morphology when exposed to tumor-derived con-
ditioned media, which was dependent on the nature of
tumor cells [20]. However, the behavior of hMSCs cul-
tured in direct contact with tumor cells has not been
studied. We established a co-culture system consisting
of GFP-labeled bone marrow-derived hMSCs in direct
contact with 12 cancer cell lines representing breast
(MCF7, BT-20, MDA-MB-231, MDA-MB-468, BT-474,
T-47D, and SK-BR-3), colon (HT-29), prostate (PC-3),
head/neck (FaDu), and skin melanoma (MDA-MB-435s).
Figure 1a–o demonstrates changes in hMSC morphology
in response to direct contact with cancer cell lines. One
remarkable change was the cellular reorganization of
hMSCs leading to the formation of a honeycomb niche-
like structure when co-cultured with MCF7, BT-20, HT-
29, and BT-474 (Fig. 1b, c, d, e). In contrast, hMSCs co-
cultured with FaDu, T47D, and PC-3 exhibited
fibroblast-like morphology and inhibition of cell growth
(Fig. 1f, h, i, l). The MDA-MB-435s cell line did not
affect the growth pattern of hMSCs (Fig. 1k). On the
other hand, co-culturing hMSCs with nontumorigenic
breast cell line MCF10A did not induce significant
changes in the morphology or growth (Fig. 1m). Co-
culture of GFP-labeled hMSCs and mcherry-labeled
MCF7 is shown in Fig. 1n, which shows the formation
of the niche-like structure by hMSCs (green), whereas
the MCF7 tumor cells (red) grew in clusters surrounded
by hMSCs. Similar morphological changes were ob-
served when primary adipose-derived human stromal
stem cells (AT-hMSCs) were co-cultured with MCF7
(Fig. 1o), suggesting that this observed response is con-
served in hMSCs derived from different tissue compart-
ments. The honeycomb structure of MCF7–hMSC
co-cultures was also observed when hMSCs were co-
cultured with MCF7 at a decreasing ratio as low as 1:64
(Fig. 1p).
The change in hMSC morphology requires direct contact
with tumor cells
We subsequently determined whether the observed
phenotype requires prerequisite direct cell–cell contact.
We repeated the experiment using hMSCs and the
MCF7 cell line with the transwell culture system, where
hMSCs were cultured in the upper chamber and MCF7
tumor cells were cultured in the lower chamber or vice
versa. As shown in Fig. 2a, b, there were no detectable
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changes in hMSC morphology or growth pattern. In
addition, we subsequently established a co-culture sys-
tem in a 35 mm dish whereby MCF7 cells were grown
as a droplet on one side of the dish and FaDu cells in
another droplet on the opposing side of the dish. When
both cell types became adherent, hMSCs were added. As
shown in Fig. 2c, d, e, f, the niche-like morphology of
hMSCs was only observed in hMSCs at the contact site
Fig. 1 Distinct morphological changes in hMSCs co-cultured with cancer cell lines. a–l GFP-labeled hMSCs were co-cultured with the indicated
tumor cell lines at a 1:2 ratio, and on day 7 of the co-culture images were taken using a Nikon® ECLIPSE Ti-U inverted fluorescence microscope
(4×). Data are representative of at least three independent experiments. m hMSCs co-cultured with normal breast epithelial cell line (MCF10A). n
hMSCs (GFP-labeled) co-cultured with MCF7 (mcherry-labeled) as above. Cells were stained with nuclear staining DAPI (blue). o AT-MSCs labeled
with DiO (green) and co-cultured with MCF7 cells labeled with DiD (red). At day 7, photomicrographs were taken using a Nikon® ECLIPSE Ti-U
inverted fluorescence microscope (magnification 4×). p MCF7 cells were co-cultured with hMSCs at the indicated ratios (tumor:MSCs), and on day
7 images were captured in the green channel (MSCs) using 4× magnification. DAPI was used to stain nuclei
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with MCF7 cells, but not with FaDu cells, corroborating
that the observed changes in hMSC morphology are
cancer cell-line specific and require direct cell–cell con-
tact between hMSCs and tumor cells.
Gene expression analysis of hMSCs sorted from MCF7 and
BT-20 co-cultures revealed enrichment for pathways
related to bone formation
To examine for the molecular changes induced in the
niche-like structures formed by hMSCs co-cultured with
MCF7 or BT-20 cells, hMSCs were negatively sorted
using immune-magnetic beads (magnetic activated cell
sorting) tagged with anti-human epithelial specific anti-
gen (ESA; EpiCAM) of co-cultured cell populations. The
procedure was repeated twice to increase the purity of
sorted hMSCs. As shown in Fig. 3a, we were able to iso-
late hMSCs from the co-culture with very high purity
(>97 %). Global gene expression analysis was determined
using the Agilent® Human SurePrint microarray chip
(G3 Human GE 8 × 60 k). We detected 218 upregulated
Fig. 2 Morphological changes in hMSCs require direct contact with cancer cells. a control hMSCs. b hMSCs cultured in the upper chamber of a
transwell culture system in which MCF7 cells were cultured in the lower chamber. c, d MCF7 cells were seeded on one side of 5 mm dish while
FaDu cells were seeded on the opposing side of the same dish, and when cells were attached hMSCs were added to the culture: hMSCs in
contact with c, d MCF7 cells or e, f FaDu cells. On day 7, photomicrographs were taken using a Nikon® ECLIPSE Ti-U inverted fluorescence
microscope (magnification 4×). GFP green fluorescent protein, hMSC human bone marrow-derived mesenchymal (stromal) stem cell, DIC
differential interference contrast
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genes and 92 downregulated genes in hMSCs sorted
from MCF7 and BT-20 co-cultures compared with con-
trol hMSCs. As shown in Fig. 3b, hierarchical clustering
revealed closer clustering of hMSCs sorted from MCF7
and BT-20 co-cultures compared with control hMSCs.
Functional categories of the upregulated genes revealed
significant enrichment for gene categories of bone forma-
tion: endochondral ossification, focal adhesion, osteoblast
signaling, and transforming growth factor beta (TGF-β)
signaling (Fig. 3c; Additional files 2 and 3). Gene expres-
sion of a selected number of genes from the microarray
data (VEGFA, SOX9, FOS, PLAU, BGN, BMP2, CDH11,
SNAI1, and SPARC) was subsequently validated using
qRT-PCR (Fig. 3d). Concordant with the microarray data,
ALP staining of hMSCs co-cultured with MCF7 revealed
a remarkable increase in ALP activity (Fig. 3e middle
panel), and ALP staining was restricted to the hMSCs and
no ALP staining was detectable in cancer cells (compare
Fig. 3e middle and right panels).
Pharmacological inhibition of FAK, MAPKK, and actin
polymerization completely abrogated niche formation by
hMSCs
Pathway analysis of upregulated genes in sorted hMSCs
revealed multiple enriched intracellular signaling path-
ways. FAK (P = 1.3 × 10−7) and MAPKK (P = 0.014) were
very prominent (Fig. 3c; Additional file 3). Upregulated
genes in the FAK pathway are highlighted and are listed
in Fig. 4a (right panel). To assess whether FAK and
MAPKK signaling are involved in induction of morpho-
logical niche-like changes of hMSC in co-cultures,
hMSCs and MCF7 cells were co-cultured as above in
the presence of PF-573228 (FAK inhibitor, 5 μM),
PD98059 (MAPKK inhibitor, 2 × 5 μM), or DMSO con-
trol. As shown in Fig. 4b, c, d, pharmacological inhibition
of FAK or MAPKK abolished the niche-like morphological
changes of hMSCs. We also postulated that the niche-like
formation of hMSCs involves reorganization in the cellu-
lar cytoskeleton. To test this hypothesis, cytochalasin D
(potent inhibitor of actin polymerization, 1 μM) was
added to the co-cultures. As shown in Fig. 4e, inhibiting
actin polymerization completely abolished the niche-like
morphological changes in hMSCs.
High expression of CDH1 and low expression of IL-1β by
tumor cells are associated with hMSC niche-like formation
To identify the molecular factors in tumor cells that pro-
mote or inhibit niche-like morphological changes in
hMSCs, gene expression datasets for the cell lines uti-
lized in the current study were retrieved from the gene
expression omnibus [GEO:GSE36133] and imported into
GeneSpring GX. Clustering analysis revealed close clus-
tering of MCF7, BT-474, T-47D, and SKB-R3, followed
by HT-29 and BT-20 (Fig. 5a). We subsequently grouped
tumor cell lines into positive cell lines that induced
hMSC morphological changes and niche-like formation
(MCF7, BT-20, HT-29, and BT-474) and negative cell
lines that did not induce morphological changes (FaDu,
MDA-MB-231, MDA-MB-435s, PC-3, MDA-MB-468,
SKB-R3, and T-47D). When comparing differentially
expressed genes between the two cell groups, we observed
CDH1 to be among the top genes highly expressed by the
positive tumor group (Fig. 5b; Additional file 4). On the
other hand, elevated expression of IL-1β was observed in
several of the negative tumor group (Fig. 5b). To deter-
mine the inhibitory effects of IL-1β on morphological
changes in hMSCs, hMSCs were co-cultured with MCF7
or HT-29 cells in the presence of vehicle or increasing
dose of recombinant human IL-1β. As shown in Fig. 5c,
significant inhibition of morphological changes and niche-
like formation in hMSCs was observed. As a corollary, we
investigated the effect of inhibiting IL-1β signaling in the
co-culture system on hMSC niche-like formation. For this
experiment, FaDu cells were chosen because they
expressed the highest levels of IL-1β (Fig. 5b). As shown
in Fig. 5d, a dose-dependent reversal into niche-like for-
mation in hMSCs was observed when FaDu cells were
co-cultured with hMSCs in the presence of increasing
concentrations of soluble recombinant IL-1 receptor
(srIL-1R). Interestingly, the niche-like formations ob-
served in FaDu-hMSCs co-cultures in the presence of
srIL-1R was indistinguishable from that observed in
MCF7-hMSC co-cultures (Fig. 1). Therefore, our data sug-
gest that tumor-derived IL-1β is a negative regulator of
hMSC niche formation. In order to assess the role of
CDH1 in niche formation, we co-cultured hMSCs with
COLO-320 (which lacks CDH1 expression) or HT-29
(See figure on previous page.)
Fig. 3 Gene expression analyses of hMSCs sorted following direct contact with either MCF7 or BT-20 cells in co-culture systems revealed
enrichment for genes related to bone formation. hMSCs were co-cultured with MCF7 or with BT-20 tumor for 7 days. The cells were trypsinized
and hMSCs were sorted using magnetic activated cell sorting technology: a efficiency of sorting. b Hierarchical clustering of control hMSCs (blue)
or hMSCs sorted from MCF7 (brown) or BT-20 (orange) co-cultures. Each column represents one replica. Expression level of each gene in a single
sample is depicted according to the color scale. c Pie chart illustrating the distribution of the top 10 GO categories for the upregulated genes in
sorted hMSCs from both MCF7 and BT-20 co-cultures. The pie section size corresponds to fold enrichment. d qRT-PCR validation of selected
genes from the microarray data. Data are presented as mean ± standard error, n = 6. **P <0.005; ***P <0.0005. e ALP staining for control hMSCs
(left) or hMSCs following co-culture with MCF7 (day 7) (middle). Representative photomicrograph of hMSCs (GFP-labeled) in co-culture with MCF7
(right). ALP alkaline phosphatase, GFP green fluorescent protein, hMSC human bone marrow-derived mesenchymal (stromal) stem cell, GO
gene ontology
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(which expresses high levels of CDH1) and studied the de-
velopment of the niche-like formation. Data presented in
Fig. 5e showed lack of niche formation in COLO-320–
hMSC co-cultures compared with the HT-29–hMSC
co-cultures, suggesting that CDH1 is potentially in-
volved in promoting niche formation possibly through
promoting homotypic cell adhesion.
Transfer of cellular components from cancer cells to
hMSCs with no evidence of cell fusion during co-culture
Data presented in Figs 1 and 2 suggest that the forma-
tion of hMSC niche-like morphological changes requires
cell–cell contact. Cancer cells were therefore labeled
with DiL or DiD lipophilic tracer dyes (which specifically
label plasma membranes). Subsequently, hMSCs and
cancer cells were co-cultured in direct contact (Fig. 6a)
or separated using a transwell culture system (Fig. 6b).
We observed noticeable transfer of cellular components
from cancer cells to hMSCs in a time-dependent manner
(~70 % on day 7), which occurred when the two cells
types were co-cultured in direct contact (compare Fig. 6a
middle and right with Fig. 6b right). In addition, fluores-
cence microscopy revealed transfer of microvesicles be-
tween fluorescence-labeled AT-MSCs and labeled MCF7
cells when co-cultured in direct contact (Additional file 5).
A previous study reported that hMSCs were able to fuse
with other cell types, such as epithelial cells, when co-
cultured in vitro [21]. In order to address whether cellular
fusion took place between hMSCs and cancer cells
under our culture conditions, GFP-labeled hMSCs were
co-cultured with mcherry-labeled MCF7 cells for 7 days.
As shown in Fig. 6c, FACS analysis revealed no evi-
dence of cellular fusion. Similarly, hMSCs from the co-
cultures did not stain for ESA—again proving lack of
cellular fusion between hMSCs and cancer cells during
co-cultures (Fig. 6c right panel). Our data suggest that
microvesicular transfer of cellular components from
tumor cells to hMSCs is a possible mechanism of cellu-
lar communication mediating morphological changes of
niche-like formation of hMSCs.
Bidirectional influence on cell growth between hMSCs
and cancer cells in co-cultures
We also examined the possible effects of hMSC niche for-
mation on cancer cell growth. hMSCs were co-cultured
with the indicated cancer cell lines, and on days 5 and 9
we employed FACS analysis to determine the percentage
of hMSCs and cancer cells in the co-culture and auto-
mated cell counting (Vi-CELL) to determine the total
number of cells. The data presented in Fig. 7 demonstrate
that in most cases (except MCF7) the cancer cell number
was usually less when co-cultured with hMSCs compared
with cancer cells cultured alone (Fig. 7a). We also ob-
served a significant reduction in the number of hMSCs
co-cultured with cancer cells that did not induce niche
formation (i.e. FaDu). Under certain conditions, we ob-
served a slight increase in hMSC number when co-
cultured with cancer cells (i.e. HT-29).
We also determined whether the ratio of cancer cells to
hMSCs is a factor in determining the outcome of co-
cultures. We cultured a fixed number of hMSCs (0.5 ×
104) with an increasing number of MCF7 (1.0 × 103, 0.5 ×
104, 1.0 × 104, 0.5 × 105) or HT-29 (1.0 × 103, 0.5 × 104,
1.0 × 104, 0.5 × 105) tumor cells. The number of hMSCs
and cancer cells on day 6 was determined. When a low
number of MCF7 cells was employed, we observed a sig-
nificant increase in the number of hMSCs compared with
hMSCs cultured alone (Fig. 7b). Similarly, time-lapse live
cell imaging microscopy revealed dynamic interaction be-
tween hMSCs and MCF7, with higher mitotic activity in
hMSCs co-cultured with MCF7 cells (Additional file 6).
On the other hand, a higher number of MCF7 cells was
observed in the hMSC–MCF7 co-cultures compared with
MCF7 cultured alone (Fig. 7b). When examining the co-
cultures of hMSCs with HT-29 cells, we also observed an
increase in the number of hMSCs (Fig. 7c). In contrast,
the number of HT-29 tumor cells decreased when co-
cultured with hMSCs, suggesting a possible anti-tumor ef-
fect of hMSCs. In order to further confirm these findings,
we utilized GFP-labeled hMSCs and MCF7 or HT-29 cells
engineered to express the firefly luciferase gene. As shown
in Fig. 7d, e, f, a rapid increase in hMSC number was ob-
served when co-cultured with MCF7 or HT-29 cells which
was associated with a significant decline in the number of
HT-29 cells and an increase in the number of MCF7 cells.
Concordant with data presented in Fig. 7a, b, f, Ki67 and
PCNA staining (markers for cell proliferation) of MCF7–
hMSC co-cultures revealed high expression of ki67 and
PCNA in MCF7 cells that are in close contact with the
hMSC niche formation (Fig. 8a, b).
(See figure on previous page.)
Fig. 4 Pharmacological inhibition of FAK, MAPKK, and actin polymerization completely abrogated hMSC morphological changes. a The FAK
pathway was among the top upregulated pathways in hMSCs following co-culture with MCF7 or BT-20 cancer cells. Matched entities are
highlighted on the chart. Morphological changes in hMSCs following: disruption of the hMSC niche structure through pharmacological inhibition
of c FAK (5 μM, PF-573228; Sigma), d MAPKK (5 μM, PD98059; Sigma) or e actin polymerization (1 μM, cytochalasin D; Sigma) compared with
dimethyl sulfoxide (DMSO)-treated controls. b. DAPI was used to stain nuclei. All inhibitors were added on day 0 except for MAKK inhibitor which
was added on day 0, and then co-cultures were supplemented with fresh inhibitor on day 2
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Discussion
Recent years have witnessed increased interest in studying
the cancer tumor microenvironment and its contribution
to tumor progression, invasion, and metastasis. However,
the precise role of MSCs—an important component of the
cancer tumor microenvironment—remains not fully
understood. In the current study, we have utilized several
cellular and molecular approaches to investigate the dy-
namic interaction between hMSCs and cancer cells. We
employed several cancer cell lines representing breast,
prostate, colon, head and neck, and melanoma. Our data
revealed that hMSC interaction with cancer cells results in
cytoskeletal and morphological reorganization leading to
the formation of niche-like structures that exert variable
effects on cancer cell growth. We also observed that can-
cer cell expression of CDH1/IL-1β is predictive for the
presence of significant biological effects of hMSCs on
tumor cells.
We observed that hMSCs exerted anti-tumor effects,
evident by a significant decline in the number of tumor
cells when co-cultured with hMSCs (Fig. 7a). Cell track-
ing and live imaging microscopy revealed a rapid in-
crease in the numbers of hMSCs when they encountered
cancer cells (Fig. 7a, c, d; Additional file 6), suggesting
that hMSCs may act as the first line of defense against
the transformed cells. Concordant with our hypothesis,
one previous study has demonstrated a protective role
for skin-derived fibroblasts in regulating transformed
keratinocytes in vivo [22].
When hMSCs were co-cultured with cancer cells with
aggressive phenotype (such as FaDu, PC-3, or MDA-
MB-231), we observed a rapid decline in the number of
hMSCs suggesting that the behavior of hMSCs is largely
dependent on the nature of cancer cells, in particular
their inflammatory status. Our data revealed that the de-
cline in hMSC number occurred when co-cultured with
cancer cells expressing high levels of IL-1β.
We previously reported that when hMSCs are exposed
to IL-1β they acquire a proinflammatory phenotype and
exhibit a decline in their multilineage differentiation po-
tential [20]. In the current study, when hMSCs were co-
cultured with IL-1β producing cancer cells, hMSCs be-
came proinflammatory cells and their number declined.
The role of IL-1β was demonstrated by the complete re-
versal in hMSC niche formation when IL-1β signaling
was blocked during hMSC–FaDu co-cultures (Fig. 5d).
We observed that hMSCs formed niche-like structures
when co-cultured with cancer cells expressing high
levels of CDH1 and lacked IL-1β (Fig. 7h). Interestingly,
our data are in line with a published report suggesting
that the inhibitory ability of hMSCs on tumor cell
growth is mediated through binding to E-cadherin
present on tumor cells [8]. Concordant with this, niche
formation was not observed when hMSCs were co-
cultured with the COLO-320 cells (which lack CDH1
expression) compared with the HT-29 cells (which ex-
press high levels of CDH1), suggesting a possible role
for CDH1 in promoting niche formation, possibly
through facilitating homotypic cell adhesion.
While we have not characterized the nature of the
hMSC niche-like formation under all co-culture condi-
tions, the hMSC niches formed in the presence of MCF7
and BT-20 cells revealed differentiation into bone-
forming osteoblastic cells, evident by microarray analysis
and positive ALP expression (Fig. 3c, e). hMSC niche-
like formations were dependent on FAK and MAPKK
signaling because pharmacological inhibition of both
pathways completely abrogated the niche-like forma-
tions. Interestingly, Navab et al. [23] have recently iden-
tified a prognostic gene expression signature derived
from CAFs isolated from lung cancer patients and re-
ported that FAK and MAPK are two major intracellular
signaling pathways activated in CAFs, which collectively
suggest the clinical relevance of our findings.
One interesting finding in our study is the transfer of
cellular components from cancer cells to hMSCs. The
transfer of membrane-derived vesicles has been reported
previously in various biological systems as a mode of
communication between adjacent cells [24, 25]. It is
plausible that changes in hMSC phenotype when co-
cultured with cancer cells are mediated via tumor-
derived factors that induce hMSC differentiation. Inter-
estingly, while morphologically similar, the niche-like
formations in hMSCs co-cultured with HT-29 did not
stain positive for ALP (Additional file 7) and exerted
negative effects on cancer cell growth (Fig. 7a, e).
(See figure on previous page.)
Fig. 5 High expression of CDH1 and low expression of IL-1β by tumor cells are associated with induction of hMSC morphological changes. a
Clustering analysis performed on basal gene expression of the employed cancer cell lines indicated close clustering for the cancer cell lines that
induce morphological changes in hMSCs (positive cell lines, blue; MCF7, BT-474, HT-29, and BT-20) relative to cancer cell lines that do not induce
morphological changes in hMSCs (negative cell lines, red). b gene expression data for CDH1 and IL-1β in cancer cell lines retrieved from
microarray data. c Complete abrogation of hMSC morphological changes when co-cultured with MCF7 (upper panels) or HT-29 (lower panels) in
the presence of increasing dose of IL-1β. d Dose-dependent reversal into hMSC niche formation when co-cultured with FaDu cells alone or in
the presence of the indicated concentrations of soluble recombinant IL-1 receptor (srIL-1R). Images were captured on day 7 and DAPI was used
to stain nuclei. e Lack of hMSC niche formation when co-cultured with COLO-320 cells (CDH1 negative/IL-1β negative) compared with the HT-29
cells (CDH1 positive/IL-1β negative). CDH1 epithelial cadherin type 1, IL interleukin
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Similarly, both HT-29 and MCF7 co-cultured with
hMSCs had less ability to close the gap during the
wound healing assay (Additional file 8). Our current hy-
pothesis is that the niche-like formation of hMSCs plays
a role in controlling cancer cell growth and spread. Our
data are in agreement with recently published data im-
plicating pericytes, which are related ontologically to
MSCs, in preventing metastasis in vivo [7].
We observed that cell growth of MCF7 increased
when co-cultured with hMSCs. Similar to our data,
Fig. 6 Transfer of cellular components from cancer cells to hMSCs but no evidence of cell fusion during co-culture. a hMSCs (GFP-labeled) were
co-cultured with MCF7 labeled with DiL (for 5 days) or DiD (for 7 days) and subsequently were subjected to FACS analysis. b hMSCs were cultured
alone (left) or were cultured in the upper chamber, while MCF7 cells labeled with DiD were cultured in the lower chamber and then cells were
subjected to FACS analysis. c hMSCs (GFP-labeled, panel 1) or MCF7 (mcherry-labeled, panel 2) were cultured alone or were co-cultured (panel 3)
and subjected to FACS analysis. Similarly, co-cultured hMSCs and MCF7 cells were stained for ESA and were subjected to FACS analysis. ESA
epithelial specific antigen, GFP green fluorescent protein, MSC mesenchymal (stromal) stem cell
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Fig. 7 Bidirectional influence on cell growth between hMSCs and cancer cell lines in co-culture. a hMSCs were co-cultured with the indicated
tumor cell lines, and on days 5 and 9 the number of hMSCs and cancer cells from either the co-cultures or from cells cultured alone were
enumerated. Data presented as mean ± standard error (SE), n = 3. A fixed number of hMSCs (0.5 × 104) was co-cultured with an increasing number
of MCF7 cells (b 1.0 × 103, 0.5 × 104, 1.0 × 104, 0.5 × 105) or HT29 cells (c 1.0 × 103, 0.5 × 104, 1.0 × 104, 0.5 × 105) and the total number of hMSCs or
tumor cells was enumerated on day 6. Data presented as mean ± SE, n = 6. d hMSCs (0.5 × 104) were co-cultured with MCF7 (0.5 × 103) or HT-29
(0.5 × 103) cells and the relative hMSC number was enumerated using a SpectraMax/M5 fluorescence spectrophotometer plate reader. Data
presented as mean ± SE. Relative number of e HT-29-Luc or f MCF7-Luc number from co-cultures was enumerated using luciferase assay on days
4 and 8. Data presented as mean ± SE, n = 6. MSC mesenchymal (stromal) stem cell; *P <0.05; **P <0.005; ***P <0.0005
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Karnoub et al. [4] showed that MCF7 is the only breast
cancer cell line to have significant increase in tumor
growth when implanted with MSCs in vivo. The bio-
logical differences between niche-like formation of
hMSCs in response to MCF7 versus that induced by
HT-29 cells are not known. However, this may be related
to differences in multiple activated genetic pathways in
MCF7 versus HT-29 as revealed by differences in their
molecular signature (Additional file 9). We propose a
working hypothesis in which MSCs interact with cancer
cells and the outcome of this dynamic interaction is
dependent on the expression of CDH1/IL-1β by cancer
cells (Fig. 8c). MSCs exert inhibitory effects on cancer
cell growth. However, it is possible that this interaction
may also exert selection pressure on certain types of
cancer cells leading to increased cancer cell growth and
possibly metastases (Fig. 8c). Detailed molecular analysis
of this hypothesis remains to be determined.
Conclusions
Our data revealed dynamic bidirectional interaction be-
tween hMSCs and tumor cells. Data also show that this
interaction is dependent on the nature rather than the
type of tumor cells and that CDH1 and IL-1β expression
by tumor cells are key factors in determining the out-
come of hMSC–tumor cross-talk.
Additional files
Additional file 1: Is Table S1 presenting primer sequences used for
qRT-PCR. (DOCX 16 kb)
Additional file 2: Is Table S2 presenting upregulated genes in
sorted MSCs from MCF7 and BT-20 co-cultures. (XLSX 19 kb)
Additional file 3: Is Table S3 presenting the top enriched pathways
in upregulated genes in sorted MSCs from MCF7 and BT-20
co-cultures. (XLSX 12 kb)
Fig. 8 Increased proliferation of MCF7 when co-cultured with hMSCs. MCF7 cells were co-cultured with hMSCs, and on day 7 cells were fixed and
stained with the proliferation markers a Ki67 or b PCNA. Control staining is shown on each left panel. Arrowhead indicates cells with high Ki67 or
PCAN staining. c Schema depicting possible interaction between hMSCs and tumor cells. Tumor cells with high CDH1 and low IL-1β will promote
niche formation which might inhibit or promote tumor growth. Tumors with low CDH1 and high IL-1β will lead to rapid decline in hMSC
numbers, and vice versa the number of tumor cells will decline as well and the hMSC niche will not form. Selective pressure exerted by MSCs could
lead to regression of primary tumors and the acquisition of metastatic phenotype by tumor cells. GFP green fluorescent protein, IL interleukin, MSC
mesenchymal (stromal) stem cell
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Additional file 4: Is Table S4 presenting genes differentially
expressed between positive and negative tumors. (XLSX 31 kb)
Additional file 5: Is Figure S1 showing transfer of cellular
components between hMSCs and cancer cells. (DOCX 214 kb)
Additional file 6: Is Movie S1 showing time-lapse microscopy of
MCF7 cells (red) co-cultured with hMSCs (green). Images were taken
every 30 minutes using Nikon® BioStation IM-Q. (AVI 752 kb)
Additional file 7: Is Figure S2 showing ALP staining for hMSC–HT-29
co-culture. (DOCX 409 kb)
Additional file 8: Is Figure S3 showing the scratch assay for HT-29
and MCF7, alone or co-cultured with hMSCs. (DOCX 308 kb)
Additional file 9: Is Table S5 presenting the top pathways for MCF7
versus HT-29. (XLSX 15 kb)
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